GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating reiterated by equities research analysts at Societe Generale in a research note issued to investors on Thursday, StockRatingsNetwork reports. They currently have a GBX 2,000 ($30.21) target price on the stock. Societe Generale’s target price indicates a potential upside of 15.81% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley cut their price target on shares of GlaxoSmithKline from GBX 1,710 ($25.83) to GBX 1,370 ($20.69) in a research note to investors on Tuesday. Finally, analysts at Bank of America Corp. reiterated a “buy” rating on shares of GlaxoSmithKline in a research note to investors on Monday. They now have a GBX 1,800 ($27.19) price target on the stock.
Six research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of GBX 1,714.71 ($25.90).
GlaxoSmithKline (LON: GSK) traded down 1.39% on Thursday, hitting GBX 1703.0001. GlaxoSmithKline has a 1-year low of GBX 1314.00 and a 1-year high of GBX 1816.00. The stock’s 50-day moving average is currently GBX 1437.31. The company’s market cap is £82.493 billion.
GlaxoSmithKline plc (LON: GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.